home / stock / mgen / mgen quote
Last: | $23.01 |
---|---|
Change Percent: | -0.09% |
Open: | $23.29 |
Close: | $23.01 |
High: | $23.9 |
Low: | $22.9701 |
Volume: | 44,316 |
Last Trade Date Time: | 01/19/2021 04:56:03 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$23.01 | $23.29 | $23.01 | $23.9 | $22.9701 | 44,316 | 01-19-2021 |
$23.03 | $25.08 | $23.03 | $25.08 | $22.3 | 88,532 | 01-18-2021 |
$23.03 | $25.08 | $23.03 | $25.08 | $22.3 | 88,393 | 01-15-2021 |
$24.93 | $22.37 | $24.93 | $25.67 | $22 | 143,500 | 01-14-2021 |
$22.3 | $22.76 | $22.3 | $23.01 | $21.82 | 71,452 | 01-13-2021 |
$22.27 | $22 | $22.27 | $23.6699 | $21.5 | 149,027 | 01-12-2021 |
$21.93 | $19.4465 | $21.93 | $23.9 | $19.4465 | 383,912 | 01-11-2021 |
$18.79 | $18.06 | $18.79 | $20.98 | $17.95 | 355,676 | 01-08-2021 |
$18.4 | $16.98 | $18.4 | $18.45 | $16.683 | 102,011 | 01-07-2021 |
$16.51 | $16.64 | $16.51 | $17.2 | $16.39 | 54,645 | 01-06-2021 |
$16.69 | $17.02 | $16.69 | $17.02 | $16.51 | 29,171 | 01-05-2021 |
$17.2 | $16.45 | $17.2 | $17.29 | $16.1 | 46,194 | 01-04-2021 |
$16.45 | $19 | $16.45 | $19.16 | $16.45 | 60,936 | 01-01-2021 |
$16.45 | $19 | $16.45 | $19.16 | $16.45 | 60,935 | 12-31-2020 |
$16.8 | $16.32 | $16.8 | $16.975 | $16.22 | 19,653 | 12-30-2020 |
$16.36 | $16.98 | $16.36 | $16.98 | $16.025 | 49,998 | 12-29-2020 |
$17.12 | $17.63 | $17.12 | $17.63 | $16.72 | 49,090 | 12-28-2020 |
$17.63 | $18.2274 | $17.63 | $18.51 | $17.63 | 38,162 | 12-25-2020 |
$17.63 | $18.2274 | $17.63 | $18.51 | $17.63 | 38,162 | 12-24-2020 |
$18.32 | $19.14 | $18.32 | $19.14 | $18.1824 | 27,103 | 12-23-2020 |
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Miragen Therapeutics Inc. Website:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...